Latest news with #Onco-Innovations
The Market Online
02-07-2025
- Business
- The Market Online
Onco-Innovations reveals new study on global applicability of lung cancer clinical trials
Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23 This content has been prepared in collaboration with Onco-Innovations Ltd. , a third-party issuer, and is intended for informational purposes only. Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study titled Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations: A Case Study using Lung-MAP S1400I , published in medRxiv in June 2025. The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems. Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period. Implications for global drug development The findings have significant implications for the future of clinical trial design and drug development. By simulating patient outcomes in advance, researchers can optimize trial parameters and better define target populations, reducing risk and accelerating development timelines. These methodologies are foundational to SynoGraph, Inka Health's next-generation causal AI platform, which aims to revolutionize drug development through globally applicable, real-world analytics. Study highlights The research focused on the Lung-MAP S1400I trial, a leading randomized study for advanced non-small cell lung cancer (NSCLC). It evaluated whether trial results could accurately predict outcomes for real-world patients in the U.S., Germany, and France—many of whom would not have qualified for the original trial due to age, comorbidities, or other factors. Key findings include: Enhanced predictive accuracy : By incorporating external clinical knowledge, the model achieved an average discrepancy of just 0.27 months (8.2 days) between predicted and actual survival outcomes. : By incorporating external clinical knowledge, the model achieved an average discrepancy of just 0.27 months (8.2 days) between predicted and actual survival outcomes. Broader applicability : The approach significantly improved the alignment of trial results with real-world outcomes, offering a scalable solution for global oncology research. : The approach significantly improved the alignment of trial results with real-world outcomes, offering a scalable solution for global oncology research. Regulatory relevance: The study supports growing demands from regulators, payers, and clinicians for evidence that reflects real-world patient experiences. Leadership insights Among the study's co-authors is Dr. Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. A globally recognized leader in oncology, Dr. Subbiah has led over 100 early-phase clinical trials and contributed to multiple FDA and EMA approvals, including tissue-agnostic therapies targeting BRAF and RET genetic alterations. He has authored more than 400 peer-reviewed publications in top-tier journals such as The New England Journal of Medicine , Nature Medicine , and JAMA Oncology . 'The ability to model outcomes for patient groups who wouldn't typically be included in clinical trials is not just a technical achievement-it's a clinical and strategic one,' he said in a news release. 'It opens the door to faster trial design, smarter expansion decisions, and better evidence for patients who are often overlooked. These kinds of tools will be essential as we push toward more globally inclusive and data-driven drug development.' Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology. Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23. Join the discussion: Find out what everybody's saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
Associated Press
02-03-2025
- Business
- Associated Press
Onco-Innovations CEO Thomas O'Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In this exclusive interview, O'Shaughnessy shared Onco-Innovations' efforts towards developing a novel treatment candidate for colorectal cancer and other solid tumours, as well as the Company's distinguished scientific team, its recent strategic acquisition of Inka Health AI, and the Company's progress toward advancing clinical trials. The interview delved into Onco-Innovations' pioneering approach to research and development regarding cancer treatment, which focuses on precision medicine to enhance the effectiveness of traditional therapies such as chemotherapy and radiation. O'Shaughnessy highlighted the Company's proprietary technology, developed by leading scientists from the University of Alberta Cancer Institute, including the use of targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue. He also discussed how the recently-acquired Inka Health AI is developing tools to leverage artificial intelligence to optimize patient identification and enhance clinical trial efficacy. Through this acquisition, he added, Onco-Innovations will continue to focus on building partnerships with research organizations such as Quantify Research, and big-pharma, such as AstraZeneca Canada, collaborations that the Company believes will play a crucial role in advancing a precision medicine approach to cancer therapeutic development. 'Being featured on Conversations That Matter gives us an incredible opportunity to share Onco-Innovations' story and reach a broader audience. It's vital for us to communicate the novel work we're doing in precision cancer therapeutic development and how we're striving to develop innovative therapies,' said Thomas O'Shaughnessy, CEO of Onco-Innovations. 'We are committed to advancing our research, accelerating clinical trials, and ultimately making a global impact in the fight against cancer.' You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Vimeo channel, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize any of the Company's technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Associated Press
21-02-2025
- Business
- Associated Press
Onco-Innovations Announces U.S. Listing on the OTCQB Market
VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H,WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its common shares have commenced trading on the OTCQB marketplace under the symbol 'ONNVF'. The Company's shares will continue to trade on the Canadian Securities Exchange under the symbol 'ONCO'. The listing on the OTCQB is a step in enhancing the Company's visibility and accessibility for U.S. investors. This milestone is expected to expand Onco-Innovations' visibility in the U.S. investment market. 'This listing marks a significant milestone for Onco-Innovations, allowing us to engage more effectively with U.S. investors and offering us the ability to expand our shareholder base. We are committed to driving innovation in oncology and believe this increased accessibility will support our long-term growth,' said Thomas O'Shaughnessy, CEO of the Company. The OTCQB Venture Market provides an established platform for early-stage and growth companies to enhance their visibility in the U.S. market. Real-time quotes and market information on Onco-Innovations can be found at About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to and the potential benefits of the Company's shares being posted for trading on the OTCQB, and the Company's prospects and business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to expand the Company's shareholder base or to attract U.S. investment interest, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
